SUMMARY To investigate the mechanisms underlying the hepatotoxicity induced by methyl dopa, we have examined sera from nine patients with liver damage following the use of the drug for evidence of sensitisation to drug altered liver cell membrane antigens using both immunofluorescence and antibody dependent cell mediated cytotoxicity. Five sera induced significant cytotoxicity to hepatocytes isolated from rabbits pretreated with methyl dopa after exposure to the mixed function oxidase inducer, Arachlor 1254. Sera from 10 patients on methyl dopa but with normal liver function and 32 patients with other drug and viral induced liver damage, gave normal cytotoxicity values. Two of the antibody positive sera gave a specific immunofluorescence pattern at the periphery of human hepatocytes when tested on liver biopsy specimens taken from patients taking methyl dopa. These findings are consistent with the view that immune mechanisms directed against drug associated antigens are involved in severe liver damage from methyl dopa administration and that metabolic activation of the drug is implicated in the generation of drug associated antigen. The need for a combination of immune and metabolic factors may explain the rarity of this condition.
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Both minor and severe forms of liver damage have been reported in patients receiving methyl dopa for the treatment of hypertension. The former consists of asymptomatic, and often transient, rises of serum transaminases and according to various reports is found in two to 10% of patients receiving the drug. [1] [2] [3] The abnormalities are usually manifest within four weeks of starting the drug. The clinically overt and more severe forms of hepatotoxicity are encountered much less frequently and the total number of such cases in the literature, according to Zimmerman, 4 Human liver microsomal fraction was prepared from normal human liver by mincing thoroughly and homogenising in 10 volumes of 0 25 mol/l sucrose, 5 mM TRIS pH 8-0, after which the total microsomal fraction was isolated by differential centrifugation. 14 Sufficient sera from four patients was available (cases 2, 3, 6, 7) together with sera from two patients with untreated autoimmune chronic active hepatitis without any ingestion of methyl dopa, were diluted 1:4 in RPMI. These diluted sera were absorbed three times with human liver microsomal fraction (2 mg protein/ml) by incubation for 45 minutes at room temperature, then for 45 minutes at 4°C. This was followed by one hour centrifugation at 100 000 g at 4°C to sediment the membrane fraction and bound antibody. Liver biopsies were obtained from two patients (5 and 7) with serological evidence of methyl dopa induced liver damage, two patients without circulating antibodies (nos 2 and 6), two patients receiving methyl dopa with pre-existing liver disease and four patients with alcoholic liver disease. Paraffin embedded sections were treated with xylene for 10 minutes at room temperature and then rehydrated in phosphate buffered saline (PBS) by five 
Results

CYTOTOXICITY STUDIES
Sera from five of the nine patients with methyl dopa associated hepatotoxicity induced significant cytotoxicity to hepatocytes isolated from rabbits pretreated with Arachlor and methyl dopa (Fig. 1) . None of the sera from patients with other forms of liver disease or those taking methyl dopa with no evidence of liver damage induced significant cytotoxicity to these hepatocytes. Cytotoxicity was observed when only one (case 5) of these sera was incubated with target cells isolated from animals treated with methyl dopa alone or methyl dopa after phenobarbitone pretreatment but none when Arachlor was given alone without methyl dopa.
In order to show that the cytotoxicity assay was antibody mediated, the five sera giving significant cytotoxicity were incubated with Arachlor and methyl dopa pretreated hepatocytes as described above. These antibody coated target cells were then incubated for a further two hours with 2 ,ug F(ab)2 fragment to human Fc 1 Cytotoxicity induced by: (a) serum from patients with methyl dopa induced liver damage to hepatocytes isolated from rabbits pretreated with methyl dopa, or after phenobarbitone or Arachlor, and: (b) Serum from patients in the control groups to hepatocytes pretreated with Arachlor-and methyl dopa. ence was seen (Fig. 2a) , with increased fluorescence at the periphery of hepatocytes. In contrast, much less staining was seen when the same sera were incubated with liver tissue from patients with methyl dopa liver damage but without circulating antibody, from two normal subjects or from patients with other liver damage but taking methyl dopa (Fig. 2b) . Furthermore, no staining was observed with all these tissues using either normal sera or else two sera from patients with methyl dopa induced liver damage but without circulating antibodies.
Discussion
The finding that just over half the patients with methyl dopa induced hepatotoxicity have a circulating antibody which reacts with the antigen present on the surface of liver cells from rabbits pretreated with Arachlor and then given methyl dopa is of considerable interest in relation to the possible mechanism of hepatotoxicity. The specificity of antibody was shown since it was not found in the serum of patients receiving the drug with no evidence of liver disease nor in any other form of liver disease. The finding in the cytotoxicity assay that the antibody reacts with a determinant present on the rabbit cell membrane indicates that a similar, if not identical, antigen is generated in humans. This is given additional support by the immunofluorescence studies.
The exact mechanism by which methyl dopa ingestion results in the generation of the new or neo-antigen remains to it may be that the common transient and mild hepatotoxicity is mediated by a direct toxic mechanism and the appearance of the less common, overt and potentially fatal drug toxicity, may be dependent both on abnormal metabolism of the drug to generate the antigen and the effect on immune function to respond to that antigen. The wide variety of liver damage observed is analogous to that found after hepatitis B viral infection where hepatotoxic cell damage is mediated by immune attack on antigen on the hepatocyte membrane: a decreased immune response leads to minimal liver damage and persistence of surface viral markers, whereas an enhanced immune response leads to massive liver cell necrosis and fulminant hepatic failure. 24 With many other drug reactions of an idiosyncratic nature, a similar spectrum of liver damage is seen.
The high incidence of patients in this series with fulminant hepatic failure associated with use of the drug, must to some extent reflect the pattern of referral consequent on the specialist interest of this Unit in fulminant hepatic failure. There have been a few other instances of fulminant hepatic failure induced by methyl dopa and it is to be stressed that all other causes of fulminant hepatic failure had been excluded in the present cases; and, furthermore, the frequency of the cytotoxic antibody was as high in this clinical group as in the non-fulminant hepatic failure cases. 
